Partner Therapeutics, Inc.
Partner Therapeutics (PTx) is a commercial biopharmaceutical company committed to improving the lives of patients with cancer and other serious diseases. They focus on developing and commercializing therapeutics that address unmet medical needs, with a mission to support patient care through science, partnerships, and expanding treatment options.
Industries
Nr. of Employees
medium (51-250)
Partner Therapeutics, Inc.
Products
Recombinant GM‑CSF therapeutic (sargramostim)
A yeast‑derived recombinant human granulocyte‑macrophage colony‑stimulating factor (rhu GM‑CSF) indicated for multiple hematopoietic and supportive care uses and investigated in additional inflammatory, infectious and neurodegenerative indications.
Monoclonal antibody for NRG1 fusion‑positive cancers (zenocutuzumab)
A targeted monoclonal antibody therapy for cancers harboring NRG1 gene fusions, subject to license/commercialization agreements for U.S. commercialization.
Recombinant GM‑CSF therapeutic (sargramostim)
A yeast‑derived recombinant human granulocyte‑macrophage colony‑stimulating factor (rhu GM‑CSF) indicated for multiple hematopoietic and supportive care uses and investigated in additional inflammatory, infectious and neurodegenerative indications.
Monoclonal antibody for NRG1 fusion‑positive cancers (zenocutuzumab)
A targeted monoclonal antibody therapy for cancers harboring NRG1 gene fusions, subject to license/commercialization agreements for U.S. commercialization.
Services
Licensing and commercialization services for late-stage oncology therapeutics, including exclusive U.S. commercialization arrangements.
Partnering with U.S. government agencies for development funding, advanced development contracts and medical countermeasure regulatory support.
Use of third‑party distribution agreements and named‑patient programs to provide product access in territories where products are not registered.
Licensing and commercialization services for late-stage oncology therapeutics, including exclusive U.S. commercialization arrangements.
Partnering with U.S. government agencies for development funding, advanced development contracts and medical countermeasure regulatory support.
Use of third‑party distribution agreements and named‑patient programs to provide product access in territories where products are not registered.
Expertise Areas
- Clinical trial management
- Biologics manufacturing and supply
- Immunomodulatory therapeutics development
- Regulatory strategy and approvals (FDA, PMDA, sBLA, orphan designation)
Key Technologies
- Recombinant protein therapeutics (rhu GM-CSF)
- Aerosolized / inhaled drug delivery
- Intravenous biologic administration
- Randomized controlled trial platforms (Phase 2–3)
News & Updates
Results from an investigator-initiated clinical trial evaluating Leukine in Parkinson’s Disease.
Pre-clinical research showing GM-CSF reversed cognitive impairment in Down syndrome models and improved cognition in aged mice.
Leukine received FDA approval for treating acute radiation syndrome, demonstrating survival benefit when initiated 48 hours after radiation exposure.
Leukine was approved by the FDA for the treatment of acute radiation syndrome, demonstrating survival benefit when initiated 48 hours after radiation exposure.
Results from an investigator-initiated clinical trial evaluating Leukine in Parkinson’s Disease.
Pre-clinical research showing GM-CSF reversed cognitive impairment in Down syndrome models and improved cognition in aged mice.
Leukine received FDA approval for treating acute radiation syndrome, demonstrating survival benefit when initiated 48 hours after radiation exposure.
Leukine was approved by the FDA for the treatment of acute radiation syndrome, demonstrating survival benefit when initiated 48 hours after radiation exposure.